NASDAQ : CBAY

CymaBay Therapeutics, Inc.

$32.48 USD

$0.01 (0.03%)

Volume
8.35M
Average Volume
4.16M
Market Capitalization
$3.73B
P/E Ratio
-32.81
Dividend Yield
0.00%
Price Target
Year High
$32.50
Year Low
$7.26
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$10.96
Company Overview

NASDAQ

Sujal A. Shah

Biotechnology

Healthcare

CBAY

101

US

USD

https://www.cymabay.com

510 293 8800

23257D103

0001042074

Liquidity Metrics

0.39

10.96

10.96

5.61

0.00

Sales & Valuation

$31.07M

119.98

11.80

-51.09

-0.69

Profitability

-$0.99

-$105.37M

-339.10%

-339.10%

-64.17%

-24.24%

P/E Metrics

-32.81

-1.11

-1.11

Analyst Price Target & Rating

N/A

0/5

23 Analysts

%

Poll Results

About CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Stock

CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical development phase, focused on discovering and delivering treatments for liver disorders and various other long-term illnesses. A key experimental therapy in their portfolio is seladelpar (MBX-8025), a selective activator of the peroxisome proliferator activated receptor delta. This compound is currently undergoing a pivotal Phase III clinical trial for primary biliary cholangitis (PBC), and has also concluded a Phase 2b study investigating its use for nonalcoholic steatohepatitis (NASH). Additionally, the company is advancing MBX-2982 through Phase 2a clinical trials, aiming to address hypoglycemia in individuals with type 1 diabetes. CymaBay maintains strategic partnerships, including a licensing arrangement with AB ... W Cyclops SPV LP to aid the development of seladelpar for PBC. They also possess a global license from Janssen Pharmaceuticals, Inc. to research, develop, and bring to market compounds active against an undisclosed metabolic disease target. Established in 1988 and formerly known as Metabolex, Inc., CymaBay Therapeutics, Inc. is headquartered in Newark, California.

Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board

2026-06-23 09:00:00

Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debili

Frequently Asked Questions

What is the current CymaBay Therapeutics, Inc. (CBAY) stock price?

CymaBay Therapeutics, Inc.(NASDAQ:CBAY) stock price is $32.48 in the last trading session. During the trading session, CBAY stock reached the peak price of $32.5 while $7.261 was the lowest point it dropped to. The percentage change in CBAY stock occurred in the recent session was 0.03% while the dollar amount for the price change in CBAY stock was $0.01.

CBAY's industry and sector of operation?

The NASDAQ listed CBAY is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of CBAY?

Charles A. McWherter | President of Research & Development and Chief Scientific Officer
Paul T. Quinlan | General Counsel, Chief Compliance Officer & Corporate Secretary
Harish Shantharam | Chief Financial Officer, Principal Accounting & Financial Officer
Robert L. Martin | Senior Vice President of Manufacturing & Nonclinical Development
Ken Boehm | Senior Vice President of Human Resources

How many employees does CBAY have?

Number of CBAY employees currently stands at 101. CBAY operates from 7575 Gateway Boulevard, Newark, CA 94560, US.

Link for CBAY official website?

Official Website of CBAY is: https://www.cymabay.com

How do I contact CBAY?

CBAY could be contacted at phone #510 293 8800 and can also be accessed through its website. CBAY operates from 7575 Gateway Boulevard, Newark, CA 94560, US.

How many shares of CBAY are traded daily?

The average number of CBAY shares traded daily for last 3 months was 4.16M.

What is the market cap of CBAY currently?

The market value of CBAY currently stands at $3.73B with its latest stock price at $32.48